Phase 4 N=58 Drug and Talk Therapy for Fibromyalgia
Fibromyalgia
Primary: Change in Weekly Average Pain Intensity — -2.1; -0.97; -1.67 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=57 Light Treatment to Improve Symptom Management of Fibromyalgia Syndrome
Fibromyalgia · FMS
Primary: Fibromyalgia Impact Questionnaire, Revised (FIQ-R) Score — 40.8; 45.3; 38.0; 39.4 score on a scale — p=0.28
N/A N=43 Transcutaneous Electrical Nerve Stimulation (TENS) and Fibromyalgia (FM)
Fibromyalgia
Primary: Pain at Rest Difference Score Pre-intervention and Post Intervention — 0.38; -0.74; -0.47 units on a scale
N/A N=301 Fibromyalgia Activity Study With Transcutaneous Electrical Nerve Stimulation (FAST)
Fibromyalgia
Primary: Pain Rating With Movement (0-10 Low to High Scale) During Six Minute Walk Test — -1.8; -0.8; 0.00; -2.0 Units on a scale — p=0.008
N/A N=200 Association of Ferritin Levels With Clinical Parameters in Patients With Fibromyalgia Syndrome
Fibromyalgia
Primary: Pitsburgh Sleep Quality Index — 8.3 score on a questionnarie
N/A N=91 The Clinical Effect of Low-Intensity Electromagnetic Field Neurostimulation in Fibromyalgia Syndrome Patients
Fibromyalgia
Primary: Change in Tender Point Pain Threshold — 19.6; -3.2 units on a scale
N/A N=20 Repetitive Transcranial Magnetic Stimulation (rTMS) in Fibromyalgia
Fibromyalgia
Primary: Visual Analog Scale-Pain — 5.30; 6.80 units on a scale
N/A N=9 Virtual Reality and Meditation for Fibromyalgia
Fibromyalgia
Primary: Pain Numerical Rating Scale [NRS] (Change From Pre-intervention to Post-intervention) — 4.4; 4.8 score on a scale
N/A N=57 Cranial Electrical Stimulation Effects on Symptoms in Persons With Fibromyalgia
Fibromyalgia
Primary: Pain Intensity Using Numeric Rating Scale — 5.12; 6.36; 6.62 units on a scale — p=0.045
N/A N=66 Tai Chi Mind-Body Therapy for Fibromyalgia
Fibromyalgia
Primary: Mean Change From Baseline of Fibromyalgia Impact Questionnaire Score — -27.8; -9.4 units on a scale
Phase 3 N=6 Safety and Efficacy of Fluoxetine in Juvenile Fibromyalgia
Juvenile Primary Fibromyalgia Syndrome (JPFS) · Fibromyalgia
Primary: Average Pain Severity Score — 62 mm
N/A N=95 Positive Affect as a Source of Resilience for Adults in Chronic Pain
Geriatric · Chronic Pain
Primary: Recruitment as Measured by Rates of Enrollment (Aim 1) — 120; 95; 22; 2 Participants
Phase 3 N=114 Coping Skills Training for Adolescents With Fibromyalgia
Fibromyalgia
Primary: Change in FDI (Functional Disability Inventory) Scores at End of Study — 21.4; 19.2; 13.4; 17.0 units on a 0-60 scale — p=0.007
Phase 2 N=63 A Proof-of-concept Study to Evaluate the Efficacy and Safety of Rozanolixizumab to Treat Adult Study Participants With Severe Fibromyalgia Syndrome
Fibromyalgia
Primary: Brief Pain Inventory Short Form (BPI-SF) Average Interference Score at 12 Weeks of Treatment — 6.30; 5.76 score on a scale — p=0.129
Phase 2 N=67 "SMART-FM": Smart-Phone Based Digital Therapeutic for Management of Fibromyalgia
Fibromyalgia
Primary: Revised Fibromyalgia Impact Questionnaire (FIQ-R) Total Score — -8.7; -3.0 score on a scale
N/A N=317 Fibromyalgia Integrative Training for Adolescents With Juvenile Fibromyalgia
Fibromyalgia · Myofascial Pain Syndrome · Muscular Diseases
Primary: Functional Disability Inventory — 25.78; 24.10; 25.96; 21.83 score on a scale
N/A N=90 Kinesiophobia in Patients With Fibromyalgia Syndrome and Chronic Neck Pain
Fibromyalgia · Neck Pain · Healthy
Primary: Tampa Scale of Kinesiophobia — 41.70; 38.33; 30.83 score on a scale
Phase 3 N=36 The Innate Central Nervous System Immune Response to an Experimental Immune Challenge in People With Fibromyalgia
Fibromyalgia
Primary: Change in Ratio of Choline/ Creatine (CHO/CR) in the Brain From Baseline to 3 Hrs Post-endotoxin Administration — -.0021; -.0058 ratio
Phase 1 N=27 An fMRI Study Of Brain Response In Patients With Fibromyalgia
Fibromyalgia
Primary: Glutamine/Creatine (Gln/Cr) and Glutamate/Creatine (Glu/Cr) Ratios Measured by Proton Magnetic Resonance Spectroscopy (1H-MRS) — 1.1751; 1.13253; 1.1046; 1.17129 ratio…
N/A N=110 Probiotic VSL#3 for the Treatment of Gastrointestinal Symptoms Associated to Fibromyalgia
Fibromyalgia · Gastrointestinal Disease
Primary: Change, From Baseline to Endpoint (12 Weeks) in the Composite Score of Abdominal Pain, Abdominal Bloating and Metheorism Each One Measured in a 0-10 Visual Analog Scale…
N/A N=31 Effects of Low Dose Naltrexone in Fibromyalgia
Fibromyalgia · Persian Gulf Syndrome
Primary: Percent Change in Pain Scores Between Baseline to End of Placebo Treatment and Between Baseline to End of LDN Treatment. — 28.8; 18.0 percentage change from baseline to…
Phase 2 N=56 Neurotropin Treatment of Fibromyalgia
Fibromyalgia
Primary: Fibromyalgia Impact Questionnaire — 49.9; 37.5; 39.9; 33.4 units on a scale
N/A N=50 Evaluation of Smell and Taste in Fibromyalgia
Fibromyalgia
Primary: Sniffin' Sticks Test Score — 25.96; 36.40 score on a scale
N/A N=40 Fibromyalgia Integrative Training for Teens
Juvenile Fibromyalgia
Primary: Average Pain Intensity — 6.26; 6.41; 4.69; 6.38 units on a scale — p=.011
N/A N=1,700 Fibromyalgia Health Outcome Study on Cost of Treatments
Fibromyalgia
Primary: Cumulative Number of Medications Taken for Fibromyalgia (FM) Over 12 Months — 5.2 medications
Phase 4 N=22 A Study to Evaluate the Effects of Milnacipran on Pain Processing and Functional MRI in Patients With Fibromyalgia
Fibromyalgia
Primary: Pain Threshold at Baseline — 2.7333; 2.583 kg/cm^2
Phase 2 N=7 Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia
Fibromyalgia
Primary: Heart Rate Beats Per Minute (BPM) - First Dose (15 mg) — 76; 67; 67; 68 Heart beats per minute
Phase 3 N=113 Growth Hormone in Neuroendocrine Dysfunction With Severe Fibromyalgia Syndrome
Fibromyalgia
Primary: Percentage of Participants With Less Than 11 Tender Points at Month 6 — 20; 22 Percentage of participants
N/A N=84 Lifestyle Physical Activity to Reduce Pain and Fatigue in Adults With Fibromyalgia
Fibromyalgia
Primary: Ambulatory Pain (Higher Values Indicate Greater Pain) — 54.6; 58.9; 46.3; 62.4 units on a scale
Phase 4 N=19 The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia
Sleep Disorders · Fibromyalgia · Sleep
Primary: Number of Awakenings After Sleep Onset (NAASO) — 39.5; 34.9 Awakenings — p=0.424